KONTAFARMA CHINA HOLDINGS LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.033 HKD | 0.00% |
|
-26.67% | -8.33% |
| May. 27 | Kontafarma China Extends $850,000 Loan | MT |
| May. 02 | Active Gains Files Winding-Up Petition Against Kontafarma China's Subsidiary | MT |
| Sales 2022 | 894M 114M | Sales 2023 | 809M 103M | Capitalization | 201M 25.73M |
|---|---|---|---|---|---|
| Net income 2022 | -41M -5.24M | Net income 2023 | -28M -3.58M | EV / Sales 2022 | 0.78 x |
| Net Debt 2022 | 448M 57.3M | Net Debt 2023 | 246M 31.48M | EV / Sales 2023 | 0.55 x |
| P/E ratio 2022 |
-6.04
x | P/E ratio 2023 |
-6.96
x | Employees | 720 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 34.03% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 week | -8.33% | ||
| 1 month | +3.12% | ||
| 3 months | -8.33% | ||
| 6 months | -5.71% | ||
| Current year | -8.33% |
1 week
0.03
0.04
1 month
0.030.05
Current year
0.030.05
1 year
0.030.05
3 years
0.030.09
5 years
0.030.31
10 years
0.032.03
| Managers | Title | Age | Since |
|---|---|---|---|
Chao Wen Jiang
CEO | Chief Executive Officer | 58 | 17-12-10 |
Man Wai Si Tou
DFI | Director of Finance/CFO | 47 | 14-11-06 |
Jie Zhang
COO | Chief Operating Officer | 41 | 20-09-02 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sze Chung Chan
BRD | Director/Board Member | 54 | 11-12-19 |
Rui Bin Zhang
BRD | Director/Board Member | 52 | 14-07-23 |
Yu Huang
BRD | Director/Board Member | 55 | 14-03-14 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-03 | 0.033 | 0.00% | 6 000 |
| 24-05-31 | 0.033 | 0.00% | 1,548,000 |
| 24-05-30 | 0.033 | -5.71% | 4,548,000 |
| 24-05-29 | 0.035 | 0.00% | 264,000 |
| 24-05-28 | 0.035 | -2.78% | 12,000 |
Delayed Quote Hong Kong S.E., June 03, 2024 at 04:08 am EDT
More quotes
Kontafarma China Holdings Ltd, formely Tongfang Kontafarma Holdings Ltd, is an investment holding company principally engaged in pharmaceutical business. The Company operates its business through two business segments. The Pharmaceutical Business segment is engaged in the manufacture and sale of prescription drugs, including chemical drugs and prescribed traditional Chinese medicines, and laboratory related products. The Fitness Business is segment is engaged in the operation of fitness centers, the provision of consultation services for fitness and health activities, as well as the operation of the franchise business for royalty fee income.
Sector
Pharmaceuticals
Calendar
2024-08-25
- Q2 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -8.33% | 23.58M | |
| +40.73% | 739B | |
| +31.73% | 598B | |
| -6.30% | 353B | |
| +15.15% | 318B | |
| +4.05% | 285B | |
| +15.43% | 240B | |
| +9.52% | 210B | |
| -5.40% | 206B | |
| +6.17% | 164B |
- Stock Market
- Equities
- 1312 Stock
